Rocket Pharmaceuticals (RCKT) Common Equity (2014 - 2026)

Rocket Pharmaceuticals has reported Common Equity for 13 years, with the latest figure at $238.0 million in Q1 2026.

• Quarterly Common Equity fell 42.24% year-over-year to $238.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $238.0 million (down 42.24% YoY) and the FY2025 annual result came in at $277.2 million, down 40.16% from the prior year.
• Common Equity slipped to $238.0 million in Q1 2026 per RCKT's latest filing, from $277.2 million in the prior quarter.
• Over five years, Common Equity peaked at $541.1 million in Q3 2023 and troughed at $238.0 million in Q1 2026.
• A 5-year average of $398.4 million and a median of $403.0 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2026: Common Equity soared 47.31% in 2023, then plunged 42.24% in 2026.
• Over 5 years, Common Equity stood at $489.7 million in 2022, then grew by 0.59% to $492.6 million in 2023, then dropped by 5.96% to $463.2 million in 2024, then plunged by 40.16% to $277.2 million in 2025, then retreated by 14.13% to $238.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $238.0 million, $277.2 million, and $313.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.